Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 2,214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Active, not recruiting Phase 3 Interventional

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1160
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 1 Interventional

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

NCT01529437
View directory record Official record
Conditions
Allergies, Allergic Rhinitis, Asthma
Interventions
sublingual immunotherapy, placebo sublingual immunotherapy
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 26, 2026, 7:43 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes Related to Arthroscopic Rotator Cuff Repair Recovery Using Incrediwear

NCT06669741
View directory record Official record
Conditions
Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Arthropathy of Left Shoulder (Disorder), Rotator Cuff Arthropathy of Right Shoulder (Disorder), Rotator Cuff Arthropathy of Bilateral Shoulders
Interventions
Placebo, Shoulder Sleeve
Device
Lead sponsor
Texas Bone and Joint
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 1 Interventional

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

NCT00269061
View directory record Official record
Conditions
Non-Insulin-Dependent Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

NCT00498173
View directory record Official record
Conditions
Autism
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 26, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

NCT02459886
View directory record Official record
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 26, 2026, 7:43 AM EDT
Not listed Phase 2 Interventional

The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor

NCT01866488
View directory record Official record
Conditions
Labor Induction
Interventions
Misoprostol, Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

NCT02413203
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 7:43 AM EDT
Recruiting Not applicable Interventional

Discogen for Low Back Pain

NCT06611397
View directory record Official record
Conditions
Disc Herniation
Interventions
Discogen Low pulsed ultrasound treatment, Discogen Sham Treatment
Device
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Multi-arm Optimization of Stroke Thrombolysis

NCT03735979
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Argatroban, Eptifibatide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

NCT04212169
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MEDI3506, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 26, 2026, 7:43 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Once Versus Twice Daily Iron Supplementation in Pregnant Women

NCT02839096
View directory record Official record
Conditions
Anemia in Pregnancy
Interventions
Placebo, Ferrous Sulfate
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotic Intervention Study

NCT06030362
View directory record Official record
Conditions
Obesity, Food Addiction
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Energy2: A Study of Health and Wellness Products on Fatigue and Other Health Outcomes

NCT06074627
View directory record Official record
Conditions
Fatigue, Energy
Interventions
Energy Placebo Control Form 1, Energy Active Study Product 1.1 Usage, Energy Active Study Product 1.2 Usage, Energy Active Study Product 1.3 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

NCT01545570
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2376497, 0.9% sodium chloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 26, 2026, 7:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

NCT01531673
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 26, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

NCT06113328
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
MK-6194, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 26, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

NCT01862939
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 26, 2026, 7:43 AM EDT
Recruiting Phase 3 Interventional

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

NCT07366034
View directory record Official record
Conditions
Fibrosing Interstitial Lung Disease
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 7:43 AM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 26, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

NCT01117987
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 26, 2026, 7:43 AM EDT